BIOMX PHGE 深 沪
等待开盘 10-01 09:30:00 美东时间
0.525
-0.005
-0.94%
华盛通- 最 高0.53
- 今 开0.52
- 成交量 15.19万股
- 最 低 0.5131
- 昨 收 0.53
- 总市值 1374.26万
- 52周最高 1.1609
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 0.34
- 委 比 97.10%
- 总股本 2617.63万
- 历史最高 119.00
- 量 比 0.74
- 振 幅 3.19%
- 历史最低 0.34
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference
BiomX's CEO, Jonathan Solomon, will present at the H.C. Wainwright conference on September 8, discussing the positive Phase 2 results of BX211 for treating diabetic foot osteomyelitis (DFO). BX211, a phage therapy targeting S. aureus, showed statistically significant reductions in ulcer size, depth, and expansion compared to placebo. The company is planning a registrational trial pending FDA feedback.
09-04 12:30
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
<p>FDA has placed a clinical hold on BiomX's Phase 2b trial of BX004 for cystic fibrosis, focusing solely on the third-party nebulizer device used to deliver the drug. The BX004 drug itself has been cleared by FDA with no concerns. BiomX has submitted additional data generated by the nebulizer's manufacturer, aiming to lift the hold. Enrollment and dosing outside the U.S. continues as planned. The company is optimistic about resolving the issue p...
08-19 12:19
BiomX GAAP EPS of -$0.19
BiomX press release (NYSE:PHGE): Q2 GAAP EPS of -$0.19. Cash balance and restricted cash as of June 30, 2025, were $15.2 million, compared to $18 million as of December 31, 2024. The decrease was prim...
08-13 19:28
BiomX Q2 EPS $(0.19) Beats $(0.33) Estimate, Cash, Cash Equivalents And Restricted Cash Of $15.2M Are Sufficient To Fund Its Operations Into Q1 Of 2026
Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational studyNature Communications publication of
08-13 18:32
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
What to Expect from BiomX's Earnings
BiomX (AMEX:PHGE) is gearing up to announce its quarterly earnings on Wednesday...
08-13 03:01
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
Biomx Inc., a clinical-stage company advancing phage therapies targeting pathogenic bacteria, announced it will report its second quarter 2025 financial results and program updates before the U.S. market open on August 13, 2025. A conference call and live webcast will be held at 8:00 AM Eastern Time to discuss the results. Registration is recommended 5 minutes before the call. The webcast will be available on the Company’s website.
08-06 12:30
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BiomX (AMEX:PHGE) shares moved upwards by 40.1% to $0.61 during Tuesda...
08-06 05:07
BiomX Inc. 13G Filing Shows Morgan Stanley Reports 7.1% Stake In Co As Of June 30, 2025
https://www.sec.gov/Archives/edgar/data/1739174/000089542125000454/xslSCHEDULE_13G_X01/primary_doc.xml
08-06 03:31
BiomX Sets 2025 Annual Meeting Date
BiomX ( ($PHGE) ) has provided an update. BiomX Inc. has announced that its 202...
07-30 22:27
